RepliCel Announces Record Year in Patents Granted
ACCESSWIRE
05 May 2021, 20:05 GMT+10
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies
VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting and/or allowance of seven patent applications since December 2020.
The two patent families involved are REPL 403 related in the RepliCel dermal injector and REPL 407 related to compositions and methods for treating and repairing tendons.
RepliCel Life Sciences, Inc.: RepliCel Announces Record Year in Patents Granted
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies
VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ( RepliCel or the Company ), a company developing next-generation regenerative medicine technologies in aesthetics and orthopedics, is pleased to announce the granting and/or allowance of seven patent applications since December 2020.
The two patent families involved are REPL 403 related in the RepliCel dermal injector and REPL 407 related to compositions and methods for treating and repairing tendons.